Oral vaccine Paclovid soon to be distributed for COVID-19 treatment

A Myanmar national-owned pharmaceutical factory, Pacific Medical Industries Ltd, has successfully produced a PACLOVID/PAXLOVID (Nirmatrelvir 150 milligrammes; Ritonavir 100 milligrammes) medicine which is the latest treatment (oral medicine) for COVID-19 disease. It is a treatment that reduces hospitalization rates and will be distributed soon.
The latest treatment (oral medicine) for COVID-19 is recommended by the health organizations of the world’s developed countries including WHO, US FDA, UK MHRA, Korea FDA and Singapore FDA as the most successful oral medicine in the treatment of COVID-19 and also received a permit by the FDA Myanmar with FDA No 2308ND012.
PACLOVID (Nirmatrelvir 150 mg; Ritonavir 100 mg) can reduce the rate of hospitalization and up to 90 per cent of the death rate for those who are seriously ill if they receive early treatment. Delta and omicron variants can also be successfully treated and children aged over 12 and weighing over 40 kg can be cured, according to the laboratory tests.
A doctor’s instruction will be needed to take this medicine for it is a prescription-only medicine-POM type. Those who want to preorder PACLOVID can contact AA Medical Products Ltd along with the request letter from the clinic/hospital or a doctor’s prescription. It will be distributed into the market including doctors treating COVID-19 disease, hospitals, clinics and medical stores. The Ministry of Health alerts that the rate of Covid infection is resurging with the high rate of domestic transmission occurring in Myanmar.—TWA/GNLM